Zobrazeno 1 - 2
of 2
pro vyhledávání: '"M Vargas Lorenzo"'
Autor:
MD Cantudo Cuenca, A Acuña Vega, MR Cantudo Cuenca, T Diaz Redondo, D Blanquez Martinez, M Vargas Lorenzo, MB Dominguez Aguado, JF Marín Pozo, F Horno Ureña
Publikováno v:
European Journal of Hospital Pharmacy. 21:A11.2-A12
Background Pancreatic cancer remains a fatal and difficult to-treat disease. Gemcitabine (G) is a cytotoxic agent that is potent against pancreatic adenocarcinoma. Nab-paclitaxel (nab-P), an albumin-bound formulation of paclitaxel, appears to decreas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4cad728e4c9a3b759836becffc45cd9
https://doi.org/10.1136/ejhpharm-2013-000436.28
https://doi.org/10.1136/ejhpharm-2013-000436.28
Autor:
MJ Barbero Hernandez, Cantudo Cuenca, R Cantudo Cuenca, MB Dominguez Aguado, C Del Moral Alcazar, F Horno Ureña, R Saldaña Soria, M Vargas Lorenzo, A Acuña Vega
Publikováno v:
European Journal of Hospital Pharmacy. 20:A117.1-A117
Background Tolvaptan is the first oral antagonist of the vasopressin V2 receptor. It is indicated in adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH). Purpose To evaluate the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f074da92f2f15f135b78fe804db1ea7
https://doi.org/10.1136/ejhpharm-2013-000276.324
https://doi.org/10.1136/ejhpharm-2013-000276.324